Atypical antipsychotic adjustments and side-effects over time in adults with intellectual disability, tardive dyskinesia, and akathisia

Journal of Developmental and Physical Disabilities

Volumn 22, Issue 5, 2010, Pages 447-461

  Matson, Johnny L ^a   Rivet, Tessa T ^a   Fodstad, Jill C ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Drug side effects; Intellectual disabilities; Matson evaluation of drug side effects; Tardive dyskinesia

Indexed keywords

EID: 77956010823     PISSN: 1056263X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10882-009-9179-z     Document Type: Article

References (44)

1. Advokat, C. D., Mayville, E. A., & Matson, J. L. (2000). Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities, 21, 75-84.
2. Aman, G. (1993). Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities. Annals of Clinical Psychiatry, 5, 171-188.
3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders-text revision (4th ed.). Washington: Author.
4. Apple, J. E. & van Hauer, G. (1999). Neuroleptic malignant syndrome associated with olanzapine therapy. Psychosomatics, 40, 267-268.
5. Applegate, H., Matson, J. L., & Cherry, K. E. (1999). An evaluation of functional variables affecting severe problem behaviors in adults with mental retardation by using the questions about behavioral function scale (QABF). Research in Developmental Disabilities, 20, 229-237.
6. Cherry, K. E., Matson, J. L., & Paclawskyj, T. R. (1997). Psychopathology in older adults with severe and profound mental retardation. American Journal of Mental Retardation, 101, 445-458.
7. Correll, C. U., Leucht, S., & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry, 161, 414-425.
8. Danki, D., Dilbaz, N., & Okay, I. T. (2006). Severe extrapyramidal symptoms due to valproate plus low dose olanzapine: a case report. Klinik Psikofarmakoloji Bulteni, 16, 42-46.
9. Davies, L. M., Lewis, S., Jones, P. B., Barnes, T. R. E., Gaughran, F., Hayhurst, K., et al. (2007). Cost-effectiveness of first versus second-generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry, 191, 14-22.
10. de Leon, J., Greenlee, B., Barber, J., Sabaawi, M., & Singh, N. N. (2009). Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Research in Developmental Disabilities, 30, 613-669.
11. Deb, S., Sohnapapl, S. K., Soni, R., Lenotre, L., & Unwin, G. (2007). The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disability Research, 51, 766-777.
12. Gharabawi, G. M., Bossie, C. A., Lasser, R. A., Turkoz, I., Rodriguez, S., & Chouinard, G. (2005). Abnormal involuntary movement scale (AIMS) and extrapyramidal symptom rating scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophrenia Research, 77, 119-28.
13. Haw, C. & Stubbs, J. (2005). A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness. Journal of Intellectual Disability Research, 49, 858-864.
14. Holden, B. & Gitlesen, J. P. (2008). The relationship between psychiatric symptomatology and motivation of challenging behaviour: a preliminary study. Research in Developmental Disabilities, 29, 408-413.
15. Kalachnik, J. E., Sprague, R. L., & Slaw, K. M. (1998). Training clinical personnel to assess for tardive dyskinesia. Progress in Neuropsychopharmacology and Biological Psychiatry, 12, 749-762.
16. Khaldi, S., Kornreich, C., Choubani, Z., & Gourevitch, R. (2008). Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale, 34, 618-624.
17. Lee, H., Ryan, J., Mullet, G., & Lawlor, B. A. (1994). Neuroleptic malignant syndrome associated with the use of risperidone. Psychosomatics, 40, 267-268.
18. Leonard, H. & Hoheneck, D. (2006). Metabolic side effects of the atypical antipsychotic olanzapine in an inpatient population of adults with developmental disabilities. Mental Health Aspects of Developmental Disabilities, 9, 18-22.
19. Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999). Efficacy and extrapyramidal side-effects of new antipsychotics olanzapine, quetiapine, risperidone, and sertrindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51-68.
20. Matson, J. L. & Neal, D. (2009). Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview. Research in Developmental Disabilities, 30, 572-586.
21. Matson, J. L. & Wilkins, J. (2008). Antipsychotic drug use for the aggression of persons with intellectual disability. Lancet, 371, 9-10.
22. Matson, J. L., Smiroldo, B. B., Hamilton, M., & Baglio, C. S. (1997). Do anxiety disorders exist in persons with severe and profound mental retardation? Research in Developmental Disabilities, 18, 39-44.
23. Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson evaluation of drug side effects scale (MEDS). Research in Developmental Disabilities, 19, 501-506.
24. Matson, J. L., Bamburg, J. W., Cherry, K. E., & Paclawskyj, T. R. (1999). A validity study on the questions about behavioral function (QABF) scale: predicting treatment success for self-injury, aggression, and stereotypes. Research in Developmental Disabilities, 20, 163-175.
25. Matson, J. L., Bamburg, J. W., Mayville, E. A., & Logan, J. R. (2000). Tardive dyskinesia and developmental disabilities: an examination of demographics and topography in persons with dual diagnosis. British Journal of Developmental Disabilities, 46, 119-130.
26. Matson, J. L., Mayville, E. A., Bamburg, J. W., & Eckholdt, C. S. (2001). An analysis of side-effect profiles of anti-seizure medications in persons with intellectual disability using the Matson evaluation of drug side effects (MEDS). Journal of Intellectual and Developmental Disabilities, 26, 283-295.
27. Matson, J. L., Mayville, E. A., Bielecki, J., Smalls, Y., & Eckholt, C. S. (2002). Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities. Research in Developmental Disabilities, 23, 224-233.
28. Matson, J. L., Bielecki, J. M., Mayville, S. B., & Matson, M. L. (2003). Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions. Research in Developmental Disabilities, 24, 149-157.
29. Matson, J. L., Dixon, D. R., & Matson, M. L. (2005). Assessing and treating aggression in children and adolescence with developmental disabilities: a 20-year overview. Educational Psychology, 25, 151-181.
30. Matson, J. L., Rivet, T. T., & Fodstad, J. C. (2008a). Psychometric properties and participant characteristics for person with intellectual disability using the Matson evaluation of drug side-effects (MEDS). Journal of Developmental and Physical Disabilities, 20, 243-255.
31. Matson, J. L., Rivet, T. T., & Fodstad, J. C. (2008b). Matson evaluation of drug side-effects (MEDS) profiles in adults with intellectual disability, tardive dyskinesia, and akathesia. Journal of Developmental and Physical Disabilities, 20, 283-295.
32. Matson, J. L., Fodstad, J. C., & Rivet, T. T. (2008c). The convergent and divergent validity of the Matson evaluation of drug side effects and the Dyskinesia identification system condensed user scale (DISCUS). Journal of Intellectual and Developmental Disabilities, 33, 337-344.
33. Matson, J. L., Rivet, T. T., & Fodstad, J. C. (2009). Matson evaluation of drug side-effects (MEDS) profiles of selective serotonin reuptake inhibitors (SSRI) in adults with intellectual disability. Journal of Developmental and Physical Disabilities, 21, 57-68.
34. Myrbakk, E. & von Tetzchner, S. (2008). Psychiatric disorders and behavior problems in people with intellectual disability. Research in Developmental Disabilities, 29, 316-332.
35. Nasrallah, H. A. (2006). Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Annals of Clinical Psychiatry, 18, 57-62.
36. Pierre, J. M. (2005). Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention, and management. Drug Safety, 28, 191-208.
37. Rijcken, C. A. W., Monster, T. B. M., Brouwers, J. R. B. J., & de Jong-van den Berg, L. T. W. (2003). Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? Journal of Clinical Psychopharmacology, 23, 657-659.
38. Rosenheck, R. A., Leslie, D., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., et al. (2006). Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163, 2080-2089.
39. Soares-Weiser, K. & Fernandez, H. H. (2007). Tardive dyskinesia. Seminars in Neurology, 27, 159-169.
40. Sparrow, S., Balla, D., & Cicchetti, D. V. (1984). The Vineland adaptive behavior scales (Survey Form). Circle Pines: American Guidance Service.
41. Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M., Fleischhacker, W. W., et al. (2007). Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice, 61, 1356-1370.
42. Tyrer, P. & Kendall, T. (2008). The spurious advance of antipsychotic drug therapy. Lancet, 373, 4-5.
43. Tyrer, P., Oliver-Africano, P. G., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., et al. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomized controlled trial. Lancet, 371, 57-63.
44. World Health Organization (WHO). (2007). Collaborating centre for drug statistics methodology, ATC/DDD Index 2007 Retrieved October 2007. http://www. whocc. no/atcddd/